Most breast tumors from mutation carriers were ductal (17 out of 21 invasive tumors, 81%), estrogen receptor (ER) positive (91%), progesterone receptor (PR) positive (68%) and HER2 negative (85%) and the same was true for breast tumors from non-carriers. Here, ERBB2 is linked to breast neoplasm.